Successful Use of Tofacitinib in Pregnancy-Associated Linear IgA Bullous Dermatosis Refractory to Conventional Therapy:A Case ReportYing Fanga,b,c,d, Ranran Zhanga,b,c,d, Fang Wanga,b,c,d, Peiguang Wanga,b,c,d,*,#, Min Gaoa,b,c,d,*,#a Department of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei, 230032 Anhui, China.b Institute of Dermatology, Anhui Medical University, Hefei, 230032 Anhui, China.c Key Laboratory of Dermatology (Anhui Medical University), Ministry of Education, Hefei, 230032 Anhui, China.d Collaborative Innovation Center of Complex and Severe Skin Disease, Anhui Medical University, Hefei, 230032 Anhui, China.*Corr: Peiguang Wang, Department of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei, 230032 Anhui, China. Email: wpg2370@163.com(Peiguang Wang); Min Gao, Department of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei, 230032 Anhui, China. Email: ahhngm@126.com(Min Gao).#Peiguang Wang and Min Gao contributed equally to this article.Key Clinical Message: The present study reports the world’s first successful treatment of linear IgA bullous dermatosis of pregnancy with tofacitinib, suggesting that this may represent a potentially safe and effective therapeutic option, particularly for cases refractory to or complicated by adverse effects from conventional therapies.Acknowledgments: NoneData Availability Statement: The data that support the findings of this study are available from the corresponding author, Min Gao, upon reasonable request.Funding Statement: The authors received no financial support for the research.Conflict of Interest Disclosure: The author and the co- author do not have any conflict of interests.Ethical Statement: The manuscript has been submitted solely to this journal and is not published, in press, or currently submitted elsewhere. Written informed consent was obtained from the patient for publication of this case report and accompanying images.Patient Consent Statement: Written informed consent was obtained from the patient to publish this report in accordance with the journal’s patient consent policy.